New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
08:41 EDTTNXPTonix Pharmaceuticals 2.9M share Spot Secondary priced at $15.00
Roth Capital acted as lead book running manager for the offering.
News For TNXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
10:37 EDTTNXPTonix sinks after fibromyalgia drug trial doesn't meet primary endpoint
Subscribe for More Information
09:22 EDTTNXPTonix fibromyalgia drug has future despite data miss, says Roth Capital
After Tonix reported that Phase 2b data on its TNX-102 SL for the treatment of fibromyalgia missed the primary endpoint but showed activity in most secondary endpoints, Roth Capital thinks the drug has a future. The firm expects the company to attempt to conduct two Phase III trials of the drug instead of one trial, but estimates that the company does not currently have enough cash to pay for two trials. The firm now sees a 40% chance of the drug being approved, down from 60% previously. It keeps a Buy rating on the shares.
09:20 EDTTNXPOn The Fly: Pre-market Movers
Subscribe for More Information
08:03 EDTTNXPTonix Pharmaceuticals drops 56% after TNX-102 trial doesn't hit primary endpoint
Subscribe for More Information
06:53 EDTTNXPTonix Pharmaceuticals to host conference call
Subscribe for More Information
06:08 EDTTNXPTonix Pharmaceuticals announces results from Phase 2b BESTFIT trial of TNX-102
Subscribe for More Information
September 26, 2014
13:17 EDTTNXPTonix Pharmaceuticals to report top line BESTFIT results by October 15
Subscribe for More Information
07:32 EDTTNXPBioCentury to hold a conference
21st Annual NewsMakers in the Biotech Industry Conference to be held in New York on September 26.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use